Possibilities of immunotherapy in the future treatment of glial tumors

Abstract

AIM OF THE STUDY: study of the рossibilities of immunotherapy in the future treatment of glial tumors using effect  of the level of apoptosis of tumor cells on the antitumor activity of NDV and its ability to inactivate AMK, which stimulates  tumor growth in the experiment. 

MATERIALS AND RESEARCH METHODS. Used VBN, vaccine strain «H», obtained from the Institute of Virology.  DI. Ivanovsky in 1984. One of the leading causes of death according to the World Health Organization is cancer, which is  named the second cause of death in developed countries. Tumor cells of Ehrlich’s adenocarcinoma were inoculated into  mice subcutaneously in a volume of 0.2 ml (20x106 cells/ml). VBN was administered to animals intraperitoneally in a  volume of 0.5 ml on the fifth day from the subcutaneously grafted tumor, every 3–4 days for 25 days. The antitumor activity  of the virus was assessed by the weight of the tumor in the experimental and control groups, as well as by survival. 

RESULTS AND ITS DISCUSSION. When using the culture virus, the animals died after 17 days, while in the case of the  virus-containing allantoic fluid, the animals lived for 300 days (observation period). Both infectious and hemagglutinating  activity of the used VBN is the same. It can be assumed that in the first group, under the influence of NDV and embryonic  proteolytic proteins, cells in the state of apoptosis appear among the tumor tissue, which stimulates an adequate  immunological response, which determined the survival of the animals.

CONCLUSION. The ability of NDV to increase the level of apoptosis as a factor opposing mitotic activity with an increase  in the proteolytic properties of culture media in vitro suggests the possibility of such an approach in the treatment of  malignant gliomas.